| Exacerbation(s) during follow up | No exacerbation during follow up | p |
---|---|---|---|
 | (n = 25) | (n = 36) |  |
Baseline | |||
 SF36 PCS (sum score) | 76.4 [65.1–82] | 76 [64.6–81.3] | 0.92 |
 SF36 MCS (sum score) | 79.5 [72.5–84.3] | 80.1 [74.0–85.8] | 0.79 |
 EQ-5D index (score) | 0.76 [0.74–1] | 0.77 [0.76–1.00] | 0.70 |
 EQ-5D VAS (score) | 75 [70–80] | 80 [70–85] | 0.48 |
 CCQ (total score) | 1.2 [0.3–1.5] | 0.70 [0.40–1.00] | 0.22 |
 CAT (score)a | 10.5 [6–17.5] | 8 [5–13] | 0.11 |
Yearly change | |||
 SF36 PCS (sum score) | −1.51 (0.47) | −0.50 (0.53) | 0.16 |
 SF36 MCS (sum score) | −1.22 (0.54) | 0.03 (0.45) | 0.16 |
 EQ-5D index (score) | −0.022 (0.010) | −0.015 (0.012) | 0.66 |
 EQ-5D VAS (score) | −0.82 (0.47) | − 0.40 (0.35) | 0.48 |
 CCQ (total score) | 0.068 (0.025) | 0.042 (0.028) | 0.63 |
 CAT (score) | 0.91 (0.21) | −0.26 (0.25) | < 0.01 |